Clinical Trial Update: Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) [Phase 2]

View source ↗

Summary

This Clinical Trial Update reports that ipatasertib is being tested as a targeted therapy for cancers with AKT genetic alterations in the NCI MATCH program (Sub…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Malignant Solid Tumor
• Multiple Myeloma

Drugs mentioned

• ipatasertib (ipatasertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-08-26